Positive early data for Alzheimer’s natural killer cell therapy
Drug Discovery World
SEPTEMBER 16, 2024
NKGen Biotech has announced promising early interim data from the Phase I cohort trial of troculeucel, its cryopreserved autologous enhanced natural killer (NK) cell therapy for moderate Alzheimer’s disease. Early independent review of the Phase I data shows that after only three months treatment with a dose of six billion cells per treatment, the three patients in the Phase I cohort had no drug-related adverse reactions.
Let's personalize your content